LCK and acute lymphoblastic leukemia: They also showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, could induce cell death in GC-resistant T-ALL cells, and remarkably, co-treatment with dexamethasone is capable of reversing GC resistance, even at therapeutic drug concentrations.